From Prescription to Administration: A Comprehensive Review of the Pharmacist’s Role in Preventing Medication Errors

From Prescription to Administration: A Comprehensive Review of the Pharmacist’s Role in Preventing Medication Errors | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review From Prescription to Administration: A Comprehensive Review of the Pharmacist’s Role in Preventing Medication Errors Pavan Kumar Yanamadala, Lohitha Gumma, Lakshmi Prasanna Yarrabothula, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7829270/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Medication errors constitute a significant global public health issue, leading to preventable morbidity, mortality, and increased healthcare expenditures. In India, the risks are heightened by disjointed prescribing practices, polypharmacy, and insufficient staffing within healthcare systems. Pharmacists are increasingly acknowledged as vital contributors to the prevention of medication errors throughout the entire medication-use continuum. Objective: This comprehensive review seeks to consolidate existing evidence regarding the diverse roles and interventions of pharmacists in mitigating medication errors from the point of prescription to administration, and to pinpoint challenges and prospective avenues for future research. Methods: A systematic search was performed across PubMed, Scopus, Embase, Web of Science, and CINAHL for studies published between January 2010 and May 2025. The search terms encompassed “pharmacist,” “medication errors,” “medication safety,” and related terminology. Studies eligible for inclusion comprised observational studies, clinical trials, and systematic reviews that involved human participants and pharmacist-led interventions. The data were thematically analysed through narrative synthesis. Results: Pharmacists effectively engage at every stage: reviewing prescriptions, reconciling medications, verifying dispensing accuracy, educating patients, and monitoring adverse events. Evidence underscores their effectiveness in decreasing error rates, enhancing patient outcomes, and improving system safety. Significant barriers include inadequate staffing, communication deficiencies, and underutilization in the Indian context. Conclusion: Pharmacists are crucial to ensuring medication safety. The integration of their roles within healthcare systems, along with supportive policies and targeted research, is vital to maximising their contributions. Pharmacist Interventions Medication Errors Patient Safety Clinical Pharmacy Medication Reconciliation Prescribing Safety Figures Figure 1 1. INTRODUCTION 1.1 Definition and Classification of Medication Errors Medication errors (MEs) represent a significant issue within healthcare systems worldwide. The National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) defines MEs as "any preventable event that may result in or contribute to improper medication use or patient injury while the medication is under the supervision of the healthcare provider, patient, or consumer" 1 . These errors may occur throughout the entire medication-use continuum, encompassing the stages of prescribing, transcribing, dispensing, administering, and monitoring 2 . 1.2 Prevalence and Global Burden Worldwide, errors in medication administration led to considerable challenges in healthcare, with projections suggesting that 7,000 to 9,000 deaths could be avoided each year, alongside economic losses exceeding $ 42 billion annually 3 . The World Health Organisation's initiative titled "Medication Without Harm," which was initiated in 2017, established a bold objective to decrease severe avoidable medication-related harm by 50% within five years. This initiative emphasises three key focus areas: high-risk situations, transitions of care, and polypharmacy 4 . 1.3 Indian Context: Prevalence and Challenges In India, the challenges are exacerbated by an overloaded healthcare system and the absence of standardised treatment protocols. A recent review conducted by Shanmugapriya et al. (2024) 2 found that the average prevalence of medication errors in Indian hospitals ranges from 14.6% to 26.8%. Furthermore, a comprehensive audit performed at a tertiary care centre in South India disclosed that 92.2% of the documented errors were related to prescriptions, highlighting critical omissions such as drug strength, frequency, and administration route 5 . Medication errors are particularly common in intensive care units (ICUs) and emergency departments, where factors such as high patient turnover, polypharmacy, and staffing limitations heighten the risk. 1.4 Vulnerable Populations and High-Risk Drugs Medication errors have a greater impact on vulnerable populations, especially those who are pediatric, geriatric, or undergoing polypharmacy. These groups are at an increased risk due to factors such as weight-based dosing, changes in pharmacokinetics, or the presence of multiple comorbidities 6 . In Indian contexts, frequently involved drug classes encompass antibiotics, antihypertensives, NSAIDs, and insulin, all of which are categorised as high-alert medications by the Institute for Safe Medication Practices 7 . 1.5 Consequences: Morbidity, Mortality, and Economic Costs The ramifications of medication errors in clinical settings can vary from minor adverse drug reactions (ADRs) to severe, life-threatening complications. These errors frequently result in extended hospital stays, necessitating further investigations and therapeutic measures 8 . A study conducted by Mitra & Basu in 2020 9 established a correlation between medication errors and a 2.5-fold increase in the average duration of hospital stays. Furthermore, these errors exert considerable financial pressure, especially in public hospitals where reimbursement is limited and patients face substantial out-of-pocket costs. 1.6 The underutilised role of Pharmacists Pharmacists are universally acknowledged as vital contributors to the prevention of medication errors. Their specialised knowledge in pharmacotherapy, drug interactions, dose modifications, and patient counselling positions them as uniquely qualified guardians of medication safety 10 . In nations such as the U.S. and the U.K., clinical pharmacists are a requisite presence in hospital environments, where they engage actively in ward rounds, prescription reviews, and therapeutic drug monitoring 4 . Conversely, in India, this professional function remains underdeveloped, especially within the public healthcare system. Although the Pharmacy Council of India (PCI) has introduced the Pharm. D. curriculum to enhance clinical competencies, numerous institutions continue to lack organised clinical pharmacy services 11 . 1.7 Rationale for the Review There exists a distinct and thoroughly documented disparity between the existing evidence and the practices of institutions in India. While numerous studies have reported on the prevalence and patterns of medication errors, most of these investigations are confined to particular hospitals or departments, failing to extend their findings to a national or policy-oriented context. For example, Bhowmick et al. conducted a three-year study in 2020 12 within a single tertiary private hospital, whereas Chaithra et al. in 2023 5 concentrated on a singular regional centre in Karnataka—both studies identified significant patterns of errors but did not connect their findings to wider systemic frameworks. In a similar vein, Shanmugapriya et al. in 2024 2 , through a comprehensive review of the literature on Medication Errors in India, underscored the absence of multi-centre or nationally coordinated studies, and stressed the pressing necessity for an integrative synthesis of evidence focused on policy. This review bridges a notable gap by amalgamating both Indian and global evidence to investigate the various types and underlying causes of MEs within Indian hospital environments, as well as to assess pharmacist-led, evidence-based interventions. Additionally, it aspires to promote the systematic incorporation of clinical pharmacists into national patient safety initiatives and institutional policy development. By integrating findings from a range of institutions and aligning them with the frameworks established by WHO and NCC MERP, this review aims to foster changes at the practice level and stimulate discussions at the national level. 1.8 Objective of the Review The main objective is to conduct a critical analysis of the pharmacist's function in mitigating medication errors throughout the complete medication-use process. This encompasses recognising systemic shortcomings, recommending pharmacist-driven strategies, and outlining prospective avenues for enhancing medication safety frameworks in India. 2. METHODS This comprehensive review sought to systematically identify, synthesise, and assess the existing evidence regarding the pharmacist's role in mitigating medication errors throughout the entire medication use process, encompassing everything from prescription to administration. The methodology utilised stringent search strategies and selection criteria to guarantee the inclusion of pertinent and high-quality literature. 2.1 Literature Search Strategy A comprehensive investigation was performed across the electronic databases PubMed/MEDLINE, Scopus, Web of Science, Embase , and CINAHL (Cumulative Index to Nursing and Allied Health Literature) to locate pertinent peer-reviewed articles. The search strategy was developed collaboratively and refined iteratively through initial searches to guarantee both extensive coverage and precision. It included a mix of Medical Subject Headings (MeSH terms) , Embase Subject Headings (Emtree terms) , and pertinent keywords, interconnected by Boolean operators (AND, OR). The primary categories of search terms encompassed pharmacist-related interventions (for instance, " pharmacist ," " clinical pharmacist ," " pharmacy intervention "), types of medication errors and associated concepts (such as " medication error ," " adverse drug event ," " patient safety "), phases of the medication process (including " prescribing ," " dispensing ," " administration "), and outcomes of interventions (like " prevention ," " reduction ," and " identification "). To maintain both currency and relevance, the search was confined to articles published between January 2010 and May 2025. Only those articles published in English were deemed suitable for inclusion. Reference management tools, such as Zotero or Mendeley, were employed to arrange the search results, eliminate duplicates, and assist in managing citations. 2.2 Inclusion and Exclusion Criteria The articles identified during the literature search were subjected to a comprehensive two-step screening process, following predefined inclusion and exclusion criteria. 2.2.1 Inclusion Criteria Original Research studies (for instance, randomised controlled trials, observational studies, and quasi-experimental studies) that specifically examine the involvement of pharmacists in the prevention, identification, or reduction of medication errors. Comprehensive reviews and meta-analyses concerning pharmacist interventions that pertain to medication safety. Investigations that concentrate on any phase of the medication utilisation process, including prescribing, transcribing or order entry, dispensing, or administration. Publications that appear in peer-reviewed academic journals. Research involving human participants. 2.2.2 Exclusion Criteria Editorials, opinion pieces, letters to the editor, commentaries, conference abstracts, or book chapters (except for systematic reviews). Research which is primarily centred on medication errors that do not involve pharmacist interventions. Articles that are not accessible in full text or are not published in the English language. Studies concerning interventions exclusively conducted by healthcare professionals who are not pharmacists. Research involving animals or laboratory-based investigations. 2.3 Screening Process The study selection process was conducted independently by two authors (the first and second authors) to minimise selection bias. Initially, titles and abstracts of identified articles were screened based on predefined inclusion and exclusion criteria. Subsequently, full texts of potentially relevant studies were assessed for eligibility. Disagreements between the two reviewers—such as differing interpretations of eligibility criteria, unclear study relevance, or varying judgments on study quality—were resolved through discussion and mutual consensus. When consensus could not be reached, the third author was consulted to provide a final decision. This systematic approach ensures transparency and rigour in study selection 13 and is visually summarised in Fig. 1 (PRISMA flow diagram) 14 , 15 . 2.4 Data Extraction For each article included in the review, pertinent data were gathered utilising a standardised and pre-tested data extraction form. The data points that were extracted encompassed: Author(s) and the year of publication. Study design (for instance, RCT, cohort, cross-sectional). Study setting (such as hospital, community pharmacy, primary care). Characteristics of the population (including patient demographics and sample size). The specific type of medication error that was addressed (for example, prescribing errors or dispensing errors). Details regarding the pharmacist intervention (including medication reconciliation, patient counselling, and clinical review). Outcomes that were measured (such as error rate reduction, adverse drug event reduction, and cost savings). Significant findings and conclusions about the role of the pharmacist. The data extraction process was conducted by the first author and was independently verified by a second author to guarantee both accuracy and completeness. 2.5 Data Synthesis A narrative synthesis methodology 16 was utilised to analyse and present the collected data. The findings were thematically organised, primarily structured around the stages of the medication use process: prescription, transcribing/order entry, dispensing, and administration. Within each stage, pharmacist interventions, their effectiveness, and associated outcomes were thoroughly examined. Furthermore, overarching themes such as interprofessional collaboration, the impact of technology, and pharmacist-facilitated patient education were included. The synthesis also evaluated the effectiveness of these interventions within Indian and comparable low- and middle-income country (LMIC) contexts, along with challenges to their implementation and the underreporting of medication errors. Lastly, the strengths and weaknesses of the evidence base were assessed, and gaps in current research were identified to inform future investigations. 3. RESULTS A total of 29 studies that met the eligibility criteria, published from 2010 to 2024, were incorporated into this review. The majority, exceeding 65%, were prospective observational studies carried out in tertiary care hospitals located in India, covering states such as Karnataka, Tamil Nadu, Telangana, West Bengal, and Uttarakhand. The primary emphasis of most studies was on the phases of prescribing and administering medications. 3.1 Prevalence of Medication Errors The reported prevalence of medication errors exhibited considerable variation across different studies. For example, Bhowmick et al. in 2020 reported an exceptionally low rate of 0.0017% (88 errors out of 50,822 patients) in a three-year passive surveillance study conducted in Eastern India, indicating potential underreporting in passive monitoring systems 12 . Conversely, Chaithra et al. in 2023 recorded a ME rate of 26.81% in a tertiary hospital in South India, which showed a reduction from 36.11% following multiple sensitisation programs directed at healthcare professionals 5 . Kapil et al. (2020) reported a 6.11% occurrence of medication errors (MEs) in critical care settings, which included transcription errors at 44.1%, prescription errors at 40%, and administration errors at 14% 17 . 3.2 Types and Stages of Errors Prescribing errors were prevalent in nearly all studies, representing as much as 92.2% of total errors in certain reports 5 . Administration errors were also frequently observed, with Bhowmick et al. in 2020 12 noting their occurrence in 69.3% of the identified errors. In contrast, errors related to dispensing, documentation, and monitoring were significantly less common, generally falling within the range of 3–5% 12 . Kapil et al. in 2020 17 reported a 6.11% occurrence of medication errors (MEs) in critical care settings, which included transcription errors at 44.1%, prescription errors at 40%, and administration errors at 14%. In 2023, Aradhya et al. reported that there were 41.5% prescribing errors, 33.8% documentation errors, and 21.1% administration errors occurring in Intensive Care Units (ICUs) 10 . Frequently noted prescription-related errors encompassed: - Exclusion of generic medication names (73%) - Missing dosage details (48.5%) - Failure to specify routes of administration (35.2%) 3.3 Drug Classes and Severity Antibiotics, Non-steroidal Anti-Inflammatory drugs (NSAIDs), and cardiovascular medications were the most commonly linked to MEs. Ceftriaxone, Diclofenac, and Insulin emerged as the drugs most susceptible to errors, frequently referenced across various studies 2, 18 . Additionally, high-alert medications (HAMs) such as Potassium Chloride, Tramadol, and Propranolol were consistently identified as problematic. The categorisation by NCC MERP was utilised in more than 70% of the studies: - Errors classified as Category B (those that occurred but did not reach the patient) made up the majority (~94.8%) in numerous contexts. - A limited number of studies documented Category D–F errors (which did reach the patient and necessitated monitoring or intervention). 3.4 Pharmacist Interventions and Impact Clinical pharmacist-led interventions were evaluated in more than one-third of the studies included in the analysis. These interventions encompassed: - Auditing prescriptions and verifying dosages - Organising sensitisation workshops for nursing staff and junior physicians - Supplying medication safety charts, feedback forms, and reporting instruments Significantly, Mohan et al. conducted a sensitisation initiative in ICU environments in 2019 8 , which resulted in a marked decrease in prescription mistakes; however, the overall reporting continued to be low due to cultural barriers. In 2024, Shanmugapriya et al. highlighted the insufficient use of pharmacists in Indian healthcare facilities, advocating for the incorporation of clinical pharmacists into routine rounds and prescribing processes 2 . A prospective investigation conducted in 2022 by Mandeep Kumar et al. identified 271 medication errors (122.6 per 1,000 patient-days) within the intensive care unit; 86% of the recommendations made by pharmacists were accepted, which notably decreased the occurrence of preventable adverse drug events 19 . 4. DISCUSSION The findings compiled in this review highlight the complex and essential function of pharmacists in improving medication safety. At every phase of the medication use process—from prescribing through to administration and monitoring—pharmacists carry out specific interventions that not only minimise errors but also enhance clinical outcomes. In this analysis, we explore these contributions thoroughly, place their effectiveness within different healthcare environments, and emphasise the elements that influence their impact. 4.1 Prescribing Stage Identification and Correction of Prescribing Errors Kandasamy et al. conducted a cross-sectional study in 2021 involving 500 outpatient prescriptions at a corporate hospital in South India 20 . They found that at least one prescribing error occurred in 32.6% of the cases, alongside a dispensing error rate of 37.8%. The errors predominantly included incorrect dosages, omissions, and illegible handwriting, underscoring the critical need for pharmacist-led interventions during the prescription entry process. Pharmacists have played a crucial role in minimising medication omissions, such as absent dosage or frequency, and preventing drug-drug interactions. This has been achieved through a thorough clinical review of prescriptions to ensure dose accuracy and clarity, effective communication with prescribers, and comprehensive patient education. Moreover, an observational study carried out in Karnataka 21 indicated that a considerable number of prescriptions were missing vital elements, including patient demographic information, prescriber identification, and accurate dosage instructions. The absence of these components not only undermined the clarity and legality of the prescriptions but also created significant difficulties for pharmacists during the verification and dispensing stages. Incomplete prescriptions heighten the risk of errors such as providing the incorrect medication, administering the wrong dosage, or giving medication to the wrong patient, especially in high-volume outpatient environments where pharmacists are required to handle numerous prescriptions within constrained timeframes. These findings highlight the urgent necessity for pharmacist participation in the screening and validation of prescriptions, alongside the adoption of standardised prescription formats and training initiatives aimed at minimising ambiguity and enhancing interprofessional communication. 4.2 Dispensing and Transcribing Stage Error surveillance and reporting initiatives In 2018, Chalasani et al. established a non-punitive reporting system within an Indian teaching hospital, identifying 1,310 medication errors, which corresponds to a 6.4% incidence rate, across the processes of prescribing, transcribing, and administration over a span of three years 22 . Interventions included a pharmacist-led root cause analysis, provision of feedback to the staff, and recommendations for redesigning workflows. The outcomes demonstrated an enhanced culture of reporting, especially among nurses and junior doctors, along with increased transparency in the tracking of errors. 4.3 Administration & Monitoring Stage ICU-based Pharmacist Interventions Neelima Ganzi et al. in 2024 conducted a study on critically ill patients admitted in Intensive Care Units of a South Indian Tertiary Care Teaching Hospital, where pharmacists were responsible for performing medication reconciliation and reviewing dose adjustments 23 . The inclusion of clinical pharmacists within the MICU team has led to a decrease in the occurrence of medication-related problems (MRP), a reduction in both the duration of stay in the MICU and the overall hospital stay, and an enhancement in the health-related quality of life for patients. A prospective study conducted by Aghili and Kasturirangan in the ICU from 2017 to 2019 documented a total of 271 medication errors, which translates to 122.6 errors per 1,000 patient-days 24 . Among these errors, 25.8% were identified as drug–drug interactions, while 18.8% were due to non-conformance with established guidelines. The acceptance rate of pharmacist recommendations was notably high at 86%, which led to a significant reduction in preventable adverse drug events (ADEs), the duration of ICU stays, the number of transfers to higher levels of care, and mortality rates within the intervention group. The interventions undertaken by pharmacists, including modifying dosages of drugs cleared by the kidneys and emphasising the risks associated with nephrotoxicity, resulted in a decrease in detrimental drug-drug interactions and dosing mistakes, even though the precise rates of this decrease were not disclosed. In a tertiary care facility located in Gujarat, research indicated that 45.9% of hospitalised patients encountered omissions and errors in documentation throughout their stay 25 . These results emphasise the urgent necessity for pharmacist-led medication reconciliation services, especially during critical transitions of care, including admission, transfer, and discharge. Furthermore, the significant occurrence of these errors accentuates the need for educational initiatives directed at both patients and staff, led by clinical pharmacists, to raise awareness, refine documentation practices, and ultimately mitigate preventable harm related to medications. 4.4 Types of Medication Errors addressed High-Alert Medication Focus Research conducted in Intensive Care Units 22 , 23 revealed that pharmacists were able to catch insulin dosing mistakes, drug incompatibilities, duplications, and renal dosing concerns—frequently before patient exposure. Drug–Drug Interactions & Omissions A review of prescriptions in outpatient environments successfully averted potentially dangerous combinations and minimised omission errors by recognising previously unknown interactions. 4.5 Interprofessional Collaboration Pharmacist-led interventions achieve maximum effectiveness when integrated into a multidisciplinary care framework. The collaboration between pharmacists and other healthcare professionals, especially physicians and nurses, is essential not only for the successful execution of interventions but also for enhancing the overall safety culture within the institution. In various studies conducted in ICUs and MICUs across India 22 – 24 , 26 , 27 , pharmacists played a crucial role as active members of the clinical care team, engaging in ward rounds, patient case discussions, and real-time therapeutic decision-making. For instance, during the prospective ICU study conducted from 2017 to 2019 23 , structured clinical meetings between pharmacists and intensivists facilitated the swift identification and correction of drug-related problems (DRPs). These meetings involved real-time chart evaluations, the identification of high-risk medications (including insulin, anticoagulants, and nephrotoxic agents), and dose modifications based on renal or hepatic function. Notably, these interactions established a continuous feedback mechanism, where pharmacists’ recommendations were accepted by physicians in over 85% of instances and were valued for their contribution to preventing preventable adverse drug events (pADEs) and optimising therapy. Chalasani et al. in 2018 22 further illustrated how interprofessional collaboration can be institutionalised through systems-based strategies. Their pharmacist-initiated medication error reporting program included a collaborative analysis of reported incidents, incorporating insights from pharmacists, physicians, nurses, and administrative personnel. This method not only enabled precise classification and root-cause analysis of errors but also resulted in significant modifications to hospital protocols, such as the standardisation of prescription formats and the implementation of error-prevention alerts in manual prescription systems. The initiative contributed to the development of a non-punitive, learning-oriented culture, encouraging healthcare professionals at all levels to report and discuss errors without the fear of retribution. Furthermore, in environments where resources are constrained, such as public sector hospitals, pharmacists frequently assume a mediating role between clinical and administrative departments. Their participation in discussions at the policy level about formulary choices, medication usage protocols, or evaluations of drug utilisation enhances the effectiveness of patient safety initiatives. A recent study conducted in India by Neelima Ganzi et al. 23 has underscored that when pharmacists collaborate effectively with physicians and nursing staff, there is a significant enhancement not only in the safety of medications but also in the satisfaction of staff, compliance with treatment protocols, and the clarity of communication during shift changes. 4.6 Technological Integrations in Indian Medication Safety Initiatives Even though Indian studies have not yet conducted direct evaluations of systems such as Computerised Physician Order Entry (CPOE), Barcode Medication Administration (BCMA), or Electronic Health Records (EHRs), recent initiatives aimed at quality improvement reveal promising initial results. In a prominent tertiary care hospital located in Kolkata, a Point-of-Care Quality Improvement initiative, which is following WHO‑POCQI, executed software-generated prescriptions through four Plan–Do–Study–Act (PDSA) cycles 28 . This intervention led to a reduction in medication errors from a baseline of 63% to merely 10.4% over a span of nine months, thereby significantly enhancing the accuracy of doses, timing, infusion rates, and the quality of documentation. Although traditional BCMA systems have not yet achieved widespread implementation in India, the Kolkata QI project’s utilisation of computer-generated prescriptions, coupled with integrated digital checks, signifies a significant advancement towards electronic medication safety. By enhancing standardisation, improving legibility, and incorporating vital order information, this model establishes a solid groundwork for the future integration of barcoding and comprehensive EHR systems. These Indian experiences, albeit limited, offer persuasive evidence: even minor digital interventions, when paired with a structured pharmacist review, can substantially decrease medication errors and improve overall safety. They bolster broader policy recommendations aimed at expanding these technologies throughout public and private hospitals, especially when aligned with enhanced clinical pharmacy services. 4.7 Challenges and Barriers Under-reporting & Cultural Issues Passive systems miss many errors; voluntary reporting by pharmacists encourages openness, but cultural barriers remain. Workload and Resources Heavy patient loads and limited pharmacist staffing reduce the capacity for real-time prescription and administration review in multifaceted Indian settings. Authority and Collaboration Acceptance rates vary; ICU interventions saw high acceptance, while outpatient settings face resistance due to hierarchy or added workflow. 4.8 Policy and Practice Recommendations Incorporate Pharmacists into Clinical Teams Position clinical pharmacists within wards, intensive care units, and outpatient clinics to improve the review of prescriptions and provide patient counselling. Establish Structured Reporting A nationwide implementation of pharmacist-led error reporting initiatives, accompanied by anonymised multidisciplinary review forums. Adopt Technology Healthcare facilities ought to implement Computerised Physician Order Entry (CPOE), barcoding, and integrated monitoring systems concurrently with the activities of clinical pharmacists. Education and Awareness Conduct regular interprofessional training sessions aimed at promoting a non-punitive safety culture and enhancing awareness of best practices in medication safety. 4.9 Towards a Pharmacist-Driven Medication Safety Culture In summary, the results of this extensive review underscore the essential function of pharmacists in ensuring the safe use of medications throughout the healthcare spectrum. Interventions led by pharmacists—including prescription audits, dose modifications, reconciliation efforts, participation in interdisciplinary rounds, and the establishment of error reporting systems—have consistently proven their effectiveness in reducing medication errors, particularly in high-risk and resource-limited settings. Although there are ongoing institutional and technological obstacles, especially within numerous Indian healthcare environments, innovative models illustrate how focused pharmacist participation can markedly enhance patient safety outcomes. As India progresses in expanding its clinical pharmacy workforce and investigates digital advancements in healthcare delivery, the incorporation of pharmacists into patient care teams emerges as a practical, evidence-supported approach to mitigating preventable harm. The findings from this review lay a robust groundwork for the enhancement of national policies, institutional practices, and future research directed at optimising medication safety through pharmacist involvement. 5. CONCLUSION This review underscores the essential and complex role that pharmacists play in minimising medication errors throughout every phase of the medication use process—from prescription and transcribing to dispensing, administration, and monitoring. The evidence compiled from both Indian and selected international studies indicates that interventions led by pharmacists not only diminish the frequency of errors but also improve therapeutic outcomes, reduce adverse drug events, and facilitate cost-effective healthcare delivery. Clinical pharmacists are in a unique position to conduct medication reconciliation, detect drug–drug interactions, optimise dosages, educate patients, and engage in multidisciplinary care teams. In the context of Indian healthcare, despite facing infrastructural and systemic challenges, emerging research illustrates the increasing potential for pharmacist involvement in enhancing medication safety. These interventions are particularly effective in high-risk settings such as intensive care units (ICUs) and in situations where polypharmacy, inadequate documentation, or insufficient staffing elevate the likelihood of errors. Furthermore, the incorporation of pharmacists into standard clinical practices, bolstered by technological advancements like computerised physician order entry (CPOE) and electronic reporting systems, can further fortify safety protocols. To propel this advancement, there is an urgent requirement for policy-level integration of pharmacists into healthcare delivery systems, the establishment of structured reporting mechanisms, the expansion of clinical pharmacy services, and the promotion of interdisciplinary collaboration. Future research should prioritise large-scale, multi-centre studies and real-time assessments of pharmacist interventions to produce comprehensive national data. Ultimately, investing in the role of pharmacists transcends mere operational improvement—it represents a strategic necessity to ensure safer, more accountable, and patient-centred healthcare in India. 6. LIMITATIONS This review provides a thorough examination of the pharmacist's role in mitigating medication errors; however, it is important to recognise certain limitations. First, the majority of the studies included were observational, which restricts the capacity to establish causal relationships. Second, there is a notable lack of large-scale, multi-centre research from India, as most of the data is derived from individual institutions, potentially impacting the generalizability of the findings. Third, there may be publication bias present due to the omission of articles published in non-English languages and grey literature. Finally, despite careful screening processes, some pertinent studies may have been unintentionally overlooked because of limitations in database indexing or inconsistent use of keywords. 7. FUTURE DIRECTIONS Future research should focus on conducting extensive, multi-centre studies across a variety of healthcare environments in India to yield data that is both generalisable and relevant to policy-making. Furthermore, there is an urgent requirement for interventional research that assesses the effects of specific initiatives led by pharmacists, employing standardised outcome measures. The evaluation of digital tools, including electronic prescribing systems, barcoding, and real-time clinical decision support, should occur alongside the involvement of pharmacists. Moreover, it is crucial to create national-level frameworks that require the integration of clinical pharmacists into healthcare teams and the establishment of systematic medication safety reporting mechanisms. Policy measures that encourage interprofessional collaboration and formalise the role of pharmacists in ensuring medication safety are vital for achieving lasting improvements. Abbreviations ADR – Adverse Drug Reaction ADE – Adverse Drug Event BCMA – Barcode Medication Administration CINAHL – Cumulative Index to Nursing and Allied Health Literature CPOE – Computerised Physician Order Entry DRP – Drug-Related Problem EHR – Electronic Health Record HAM – High-Alert Medication ICU – Intensive Care Unit LMIC – Low- and Middle-Income Countries ME – Medication Error MICU – Medical Intensive Care Unit NCC MERP – National Coordinating Council for Medication Error Reporting and Prevention NSAID – Non-Steroidal Anti-Inflammatory Drug PDSA – Plan–Do–Study–Act pADE – Preventable Adverse Drug Event PCI – Pharmacy Council of India PRISMA – Preferred Reporting Items for Systematic Reviews and Meta-Analyses RCT – Randomised Controlled Trial WHO – World Health Organisation WHO-POCQI – World Health Organisation – Point of Care Quality Improvement Declarations 8. ACKNOWLEDGEMENTS The authors wish to convey their heartfelt appreciation to Prof. Rama Rao Nadendla, Principal of Chalapathi Institute of Pharmaceutical Sciences in Lam, Guntur, for his unwavering encouragement and assistance during the development of this review. The authors further recognise the invaluable contributions of the institutional library team for facilitating access to crucial academic databases and resources. 9. FUNDING STATEMENT No funding was received for the preparation of this review article. 10. CONFLICTS OF INTEREST The authors declare no conflicts of interest related to this work. Author Contribution PKY conceptualized the review, supervised the overall study, and critically revised the manuscript. LG performed the literature search, data extraction, and initial drafting of the manuscript. LPY contributed to data organization, synthesis of key findings, and manuscript editing. RRN provided expert guidance, validated the interpretations, and reviewed the final draft for intellectual content. All authors read and approved the final version of the manuscript. References Medication Error Definition [Internet]. Available from: https://www.nccmerp.org/about-medication-errors [Accessed 2025 Jun 8]. Shanmugapriya J, Mehta S, Garg S, Saxena T, Sharma N, Goswami G. Unravelling medication errors in Indian scholarly articles (2010–2023): A comprehensive review. Muller Journal of Medical Sciences and Research [Internet]. 2024 Jul 1;15(2):136–44. Available from: https://journals.lww.com/mjmr/fulltext/2024/15020/unraveling_medication_errors_in_indian_scholarly.9.aspx World Health Organisation: WHO. Patient safety [Internet]. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/patient-safety [Accessed 2025 Jun 8]. World Health Organisation. Medication Without Harm. Geneva: World Health Organisation; 2017. Available from: https://iris.who.int/bitstream/handle/10665/255263/WHO-HIS-SDS-2017.6-eng.pdf?sequence=1 [Accessed 2025 Jun 8]. Chaithra K, Sparshadeep E, Priyadarshini B, Rajesh B, Kavana V, Shabeena B, et al. Evaluation of pattern of medication errors in a tertiary care hospital in South India: A prospective observational study. National Journal of Physiology, Pharmacy and Pharmacology [Internet]. 2023 Jan 1;13(8):1. Available from: https://www.njppp.com/index.php?mno=157433 Rasool MF, Rehman AU, Imran I, Abbas S, Shah S, Abbas G, et al. Risk factors associated with medication errors among patients suffering from chronic disorders. Frontiers in Public Health [Internet]. 2020 Nov 19;8. Available from: https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2020.531038/full Pauldine B. Acute care [Internet]. ECRI and ISMP. 2024. Available from: https://home.ecri.org/blogs/ismp-resources/high-alert-medications-in-acute-care-settings Mohan A, Manikandan S, Ravikumar TS, Batmanabane G. Decreasing medication errors in four intensive care units of a tertiary care teaching hospital in India using a sensitisation programme. The National Medical Journal of India [Internet]. 2019 Jan 1;32(4):207. Available from: https://nmji.in/decreasing-medication-errors-in-four-intensive-care-units-of-a-tertiary-care-teaching-hospital-in-india-using-a-sensitization-programme/ Mitra M, Basu M. An analysis of medication errors in a tertiary care teaching hospital [Internet]. Available from: https://www.jrmds.in/articles/an-analysis-of-medication-errors-in-a-tertiary-care-teaching-hospital-53272.html Aradhya PJ, Ravi R, Chandra BJS, Ramesh M, Chalasani SH. Assessment of Medication Safety Incidents Associated with High-alert Medication Use in Intensive Care Setting: A Clinical Pharmacist Approach. Indian Journal of Critical Care Medicine [Internet]. 2023 Nov 28;27(12):917–22. Available from: https://www.ijccm.org/abstractArticleContentBrowse/IJCCM/64/27/12/34591/abstractArticle/Article Pharmacy Council of India. Amendment to Education Regulations, 1991 for the Diploma Course in Pharmacy [Internet]. New Delhi: Pharmacy Council of India; 2014 [cited 2025 Jun 8]. Available from: https://www.pci.nic.in/pdf/14-150%20amendment%20web.pdf Bhowmick S, Jana S, Bandyopadhyay A, Kundu D, Banerjee M, Das A, et al. Medication errors reported in a tertiary care private hospital in Eastern India: a three-year experience. International Journal of Basic & Clinical Pharmacology [Internet]. 2020 May 21;9(6):937. Available from: https://www.ijbcp.com/index.php/ijbcp/article/view/4124 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ [Internet]. 2009 Jul 21;339(jul21 1): b2535. Available from: https://www.bmj.com/content/339/bmj.b2535 Haddaway, N. R., Page, M. J., Pritchard, C. C., & McGuinness, L. A. (2022). PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis Campbell Systematic Reviews, 18, e1230. https://doi.org/10.1002/cl2.1230 PRISMA Flow Diagram [Internet]. Available from: https://estech.shinyapps.io/prisma_flowdiagram/ Arai L, Rodgers A, Roberts H, Popay J, Roen K, Wright N. Testing methodological developments in the conduct of narrative synthesis: a demonstration review of research on the implementation of smoke alarm interventions [Internet]. Lancaster: Lancaster University; 2007 [cited 2025 Jun 8]. Available from: https://www.lancaster.ac.uk/media/lancaster-university/content-assets/documents/fhm/dhr/chir/Rodgersetal.pdf Zirpe KG, Seta B, Gholap S, Aurangabadi K, Gurav SK, Deshmukh AM, et al. Incidence of Medication Error in Critical Care Unit of a Tertiary Care Hospital: Where Do We Stand? Indian J Crit Care Med 2020;24(9):799–803.Available from: https://www.ijccm.org/doi/pdf/10.5005/jp-journals-10071-23556 Mugada V, Devineni RC, Pendyala RM, Vempati D, Kuchi S. Categorisation, Appraisal, and Reporting of Medication Errors Ascertained in Medical Ward of Tertiary Care Hospital. J App Pharm Sci [Internet]. 2018 [cited 2025 Jun 8];8(05):109–14. Available from: https://japsonline.com/admin/php/uploads/2632_pdf.pdf Kumar M, Sahni N, Shafiq N, Yaddanapudi LN. Medication prescription errors in the intensive care unit: Prospective observational study. Indian J Crit Care Med. 2022 May;26(5):555-559. Available from: https://www.ijccm.org/doi/pdf/10.5005/jp-journals-10071-24148 Kandasamy G, Sivanandy P, Almaghaslah D, Almanasef M, Vasudevan R, Chinnadhurai M, et al. A cross‐sectional study on prescribing and dispensing errors at a corporate hospital in South India. International Journal of Clinical Practice [Internet]. 2021 Jun 11;75(9). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/ijcp.14489 P RA, Vishwas HN, Hosur SS, K A V, S K. A study of prescription errors in South Indian City, Karnataka- An observational study. IP International Journal of Comprehensive and Advanced Pharmacology [Internet]. 2023 May 15;8(2):125–9. Available from: https://www.ijcap.in/html-article/18897 Chalasani SH, Ramesh M, Gurumurthy P. Pharmacist-Initiated Medication Error-Reporting and Monitoring Programme in a developing country scenario. Pharmacy [Internet]. 2018 Dec 14;6(4):133. Available from: https://www.mdpi.com/2226-4787/6/4/133 Ganzi N, Sanathan SR, Jayaram SCB, Vigneshwaran E. Clinical Pharmacist-Initiated Interventions for Medication-Related Problems in the Medical Intensive Care Unit of a teaching university hospital in South India: a prospective observational study. International Journal of Pharmaceutical Investigation [Internet]. 2024 Dec 5;15(1):131–7. Available from: https://jpionline.org/article/33884 Aghili M, Kasturirangan MN. A clinical pharmacist-led integrated approach for evaluation of medication errors among medical intensive care unit patients. JBI Evidence Implementation [Internet]. 2020 Jun 9;19(1):21–30. Available from: https://journals.lww.com/ijebh/abstract/2021/03000/a_clinical_pharmacist_led_integrated_approach_for.5.aspx Patel S, Patel A, Patel V, Solanki N. Study of medication error in hospitalised patients in a Tertiary Care hospital. Indian Journal of Pharmacy Practice [Internet]. 2018 Mar 6;11(1):32–6. Available from: https://www.researchgate.net/publication/323589950_Study_of_Medication_Error_in_Hospitalised_Patients_in_Tertiary_Care_Hospital Pote S, Tiwari P, D’Cruz S. Medication prescribing errors in a public teaching hospital in India: a prospective study [Internet]. Available from: https://scielo.isciii.es/scielo.php?script=sci_abstract&pid=S1885642X2007000100003&lng=es&nrm=iso&tlng=en Hisham M, Sivakumar MN, Veerasekar G. Impact of clinical pharmacist in an Indian intensive care unit. Indian J Crit Care Med . 2016;20(2):78–83. Available from: https://www.ijccm.org/doi/pdf/10.4103/0972-5229.175931 Mondal S, Banerjee M, Mandal S, Mallick A, Das N, Basu B, et al. An initiative to reduce medication errors in the neonatal care unit of a tertiary care hospital, Kolkata, West Bengal: a quality improvement report. BMJ Open Quality [Internet]. 2022 May 11;11(Suppl 1): e001468. Available from: https://bmjopenquality.bmj.com/content/11/Suppl_1/e001468 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7829270","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":527814008,"identity":"862c4a5c-a08b-412b-8e4b-20e5af5f1771","order_by":0,"name":"Pavan Kumar Yanamadala","email":"data:image/png;base64,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","orcid":"","institution":"Chalapathi Institute of Pharmaceutical Sciences","correspondingAuthor":true,"prefix":"","firstName":"Pavan","middleName":"Kumar","lastName":"Yanamadala","suffix":""},{"id":527814009,"identity":"a5baca52-750b-4ee3-b5f7-3c14b2cedc34","order_by":1,"name":"Lohitha Gumma","email":"","orcid":"","institution":"Chalapathi Institute of Pharmaceutical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Lohitha","middleName":"","lastName":"Gumma","suffix":""},{"id":527814011,"identity":"cd11114e-851f-4fc2-bd33-8c1211465f96","order_by":2,"name":"Lakshmi Prasanna Yarrabothula","email":"","orcid":"","institution":"Chalapathi Institute of Pharmaceutical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Lakshmi","middleName":"Prasanna","lastName":"Yarrabothula","suffix":""},{"id":527814013,"identity":"11472310-87ea-4a68-96ab-290ae29f18eb","order_by":3,"name":"Rama Rao Nadendla","email":"","orcid":"","institution":"Chalapathi Institute of Pharmaceutical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Rama","middleName":"Rao","lastName":"Nadendla","suffix":""}],"badges":[],"createdAt":"2025-10-10 17:23:14","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7829270/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7829270/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":93369139,"identity":"247ed5bd-bfae-46c3-a54c-7c6d2ca2e27c","added_by":"auto","created_at":"2025-10-13 06:08:10","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":117065,"visible":true,"origin":"","legend":"","description":"","filename":"ManuscriptFileYPK.docx","url":"https://assets-eu.researchsquare.com/files/rs-7829270/v1/322769195f78bd21843d20cc.docx"},{"id":93368902,"identity":"57ee1ffa-bc93-42f9-8cef-57ae35be625d","added_by":"auto","created_at":"2025-10-13 06:00:10","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":6376,"visible":true,"origin":"","legend":"","description":"","filename":"a61d97ae27734f29a172e71beb8ea87a.json","url":"https://assets-eu.researchsquare.com/files/rs-7829270/v1/c3efeb2897042e7fec2f8952.json"},{"id":93368126,"identity":"42c76967-e53f-4c73-a8b7-33d6b4f10070","added_by":"auto","created_at":"2025-10-13 05:52:10","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":96832,"visible":true,"origin":"","legend":"","description":"","filename":"a61d97ae27734f29a172e71beb8ea87a1enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7829270/v1/18635a69ddb4a099fc7d679f.xml"},{"id":93368121,"identity":"6aa1a7ea-36e1-4ad7-a296-bbeca290d334","added_by":"auto","created_at":"2025-10-13 05:52:10","extension":"png","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":42431,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7829270/v1/bde17c55146be6f70c675c43.png"},{"id":93368124,"identity":"fb77ebbb-679c-4be3-9f9c-73dd4c677ae4","added_by":"auto","created_at":"2025-10-13 05:52:10","extension":"xml","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":95299,"visible":true,"origin":"","legend":"","description":"","filename":"a61d97ae27734f29a172e71beb8ea87a1structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7829270/v1/ec3603f84f645ee1c4baa032.xml"},{"id":93368125,"identity":"88267885-13b2-41dd-8b15-68692f2869ea","added_by":"auto","created_at":"2025-10-13 05:52:10","extension":"html","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":106678,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7829270/v1/8851702db8b339d0cb2ef486.html"},{"id":93368122,"identity":"359a549c-2c08-4fda-aef8-09fcda4e1ce2","added_by":"auto","created_at":"2025-10-13 05:52:10","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":65568,"visible":true,"origin":"","legend":"\u003cp\u003ePRISMA Flow Diagram illustrating the identification, screening, and selection process of studies incorporated in the review concerning the pharmacist’s role in preventing medication errors. From an initial pool of 840 records identified, 29 studies fulfilled the eligibility criteria following the removal of duplicates and the exclusion of studies that did not satisfy the inclusion criteria.\u003c/p\u003e","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7829270/v1/0186c953933b167068542eaa.jpeg"},{"id":95193787,"identity":"3ebf8657-b712-4803-a69a-1eb4c544defc","added_by":"auto","created_at":"2025-11-05 10:54:30","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1382486,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7829270/v1/fb4b2933-31d6-4d21-b6c4-4cf8993fd2aa.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003eFrom Prescription to Administration: A Comprehensive Review of the Pharmacist’s Role in Preventing Medication Errors\u003c/p\u003e","fulltext":[{"header":"1. INTRODUCTION","content":"\u003cdiv id=\"Sec2\" class=\"Section2\"\u003e\u003ch2\u003e1.1 Definition and Classification of Medication Errors\u003c/h2\u003e\u003cp\u003eMedication errors (MEs) represent a significant issue within healthcare systems worldwide. The National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) defines MEs as \"any preventable event that may result in or contribute to improper medication use or patient injury while the medication is under the supervision of the healthcare provider, patient, or consumer\"\u003csup\u003e\u003cb\u003e1\u003c/b\u003e\u003c/sup\u003e. These errors may occur throughout the entire medication-use continuum, encompassing the stages of prescribing, transcribing, dispensing, administering, and monitoring\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003e1.2 Prevalence and Global Burden\u003c/h2\u003e\u003cp\u003eWorldwide, errors in medication administration led to considerable challenges in healthcare, with projections suggesting that 7,000 to 9,000 deaths could be avoided each year, alongside economic losses exceeding \u003cspan\u003e$\u003c/span\u003e42\u0026nbsp;billion annually\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. The World Health Organisation's initiative titled \"Medication Without Harm,\" which was initiated in 2017, established a bold objective to decrease severe avoidable medication-related harm by 50% within five years. This initiative emphasises three key focus areas: high-risk situations, transitions of care, and polypharmacy\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e\u003ch2\u003e1.3 Indian Context: Prevalence and Challenges\u003c/h2\u003e\u003cp\u003eIn India, the challenges are exacerbated by an overloaded healthcare system and the absence of standardised treatment protocols. A recent review conducted by Shanmugapriya et al. (2024)\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e found that the average prevalence of medication errors in Indian hospitals ranges from 14.6% to 26.8%. Furthermore, a comprehensive audit performed at a tertiary care centre in South India disclosed that 92.2% of the documented errors were related to prescriptions, highlighting critical omissions such as drug strength, frequency, and administration route\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. Medication errors are particularly common in intensive care units (ICUs) and emergency departments, where factors such as high patient turnover, polypharmacy, and staffing limitations heighten the risk.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\u003ch2\u003e1.4 Vulnerable Populations and High-Risk Drugs\u003c/h2\u003e\u003cp\u003eMedication errors have a greater impact on vulnerable populations, especially those who are pediatric, geriatric, or undergoing polypharmacy. These groups are at an increased risk due to factors such as weight-based dosing, changes in pharmacokinetics, or the presence of multiple comorbidities\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. In Indian contexts, frequently involved drug classes encompass antibiotics, antihypertensives, NSAIDs, and insulin, all of which are categorised as high-alert medications by the Institute for Safe Medication Practices\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e\u003ch2\u003e1.5 Consequences: Morbidity, Mortality, and Economic Costs\u003c/h2\u003e\u003cp\u003eThe ramifications of medication errors in clinical settings can vary from minor adverse drug reactions (ADRs) to severe, life-threatening complications. These errors frequently result in extended hospital stays, necessitating further investigations and therapeutic measures\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. A study conducted by Mitra \u0026amp; Basu in 2020\u003csup\u003e\u003cb\u003e9\u003c/b\u003e\u003c/sup\u003e established a correlation between medication errors and a 2.5-fold increase in the average duration of hospital stays. Furthermore, these errors exert considerable financial pressure, especially in public hospitals where reimbursement is limited and patients face substantial out-of-pocket costs.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\u003ch2\u003e1.6 The underutilised role of Pharmacists\u003c/h2\u003e\u003cp\u003ePharmacists are universally acknowledged as vital contributors to the prevention of medication errors. Their specialised knowledge in pharmacotherapy, drug interactions, dose modifications, and patient counselling positions them as uniquely qualified guardians of medication safety\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. In nations such as the U.S. and the U.K., clinical pharmacists are a requisite presence in hospital environments, where they engage actively in ward rounds, prescription reviews, and therapeutic drug monitoring\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. Conversely, in India, this professional function remains underdeveloped, especially within the public healthcare system. Although the Pharmacy Council of India (PCI) has introduced the Pharm. D. curriculum to enhance clinical competencies, numerous institutions continue to lack organised clinical pharmacy services\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003e1.7 Rationale for the Review\u003c/h2\u003e\u003cp\u003eThere exists a distinct and thoroughly documented disparity between the existing evidence and the practices of institutions in India. While numerous studies have reported on the prevalence and patterns of medication errors, most of these investigations are confined to particular hospitals or departments, failing to extend their findings to a national or policy-oriented context. For example, Bhowmick et al. conducted a three-year study in 2020\u003csup\u003e\u003cb\u003e12\u003c/b\u003e\u003c/sup\u003e within a single tertiary private hospital, whereas Chaithra et al. in 2023\u003csup\u003e\u003cb\u003e5\u003c/b\u003e\u003c/sup\u003e concentrated on a singular regional centre in Karnataka\u0026mdash;both studies identified significant patterns of errors but did not connect their findings to wider systemic frameworks. In a similar vein, Shanmugapriya et al. in 2024\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e, through a comprehensive review of the literature on Medication Errors in India, underscored the absence of multi-centre or nationally coordinated studies, and stressed the pressing necessity for an integrative synthesis of evidence focused on policy.\u003c/p\u003e\u003cp\u003eThis review bridges a notable gap by amalgamating both Indian and global evidence to investigate the various types and underlying causes of MEs within Indian hospital environments, as well as to assess pharmacist-led, evidence-based interventions. Additionally, it aspires to promote the systematic incorporation of clinical pharmacists into national patient safety initiatives and institutional policy development. By integrating findings from a range of institutions and aligning them with the frameworks established by WHO and NCC MERP, this review aims to foster changes at the practice level and stimulate discussions at the national level.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e\u003ch2\u003e1.8 Objective of the Review\u003c/h2\u003e\u003cp\u003eThe main objective is to conduct a critical analysis of the pharmacist's function in mitigating medication errors throughout the complete medication-use process. This encompasses recognising systemic shortcomings, recommending pharmacist-driven strategies, and outlining prospective avenues for enhancing medication safety frameworks in India.\u003c/p\u003e\u003c/div\u003e"},{"header":"2. METHODS","content":"\u003cp\u003eThis comprehensive review sought to systematically identify, synthesise, and assess the existing evidence regarding the pharmacist's role in mitigating medication errors throughout the entire medication use process, encompassing everything from prescription to administration. The methodology utilised stringent search strategies and selection criteria to guarantee the inclusion of pertinent and high-quality literature.\u003c/p\u003e\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\u003ch2\u003e2.1 Literature Search Strategy\u003c/h2\u003e\u003cp\u003eA comprehensive investigation was performed across the electronic databases \u003cb\u003ePubMed/MEDLINE, Scopus, Web of Science, Embase\u003c/b\u003e, and \u003cb\u003eCINAHL\u003c/b\u003e (Cumulative Index to Nursing and Allied Health Literature) to locate pertinent peer-reviewed articles.\u003c/p\u003e\u003cp\u003eThe search strategy was developed collaboratively and refined iteratively through initial searches to guarantee both extensive coverage and precision. It included a mix of \u003cb\u003eMedical Subject Headings (MeSH terms)\u003c/b\u003e, \u003cb\u003eEmbase Subject Headings (Emtree terms)\u003c/b\u003e, and pertinent keywords, interconnected by \u003cb\u003eBoolean operators (AND, OR).\u003c/b\u003e The primary categories of search terms encompassed pharmacist-related interventions (for instance, \"\u003cb\u003epharmacist\u003c/b\u003e,\" \"\u003cb\u003eclinical pharmacist\u003c/b\u003e,\" \"\u003cb\u003epharmacy intervention\u003c/b\u003e\"), types of medication errors and associated concepts (such as \"\u003cb\u003emedication error\u003c/b\u003e,\" \"\u003cb\u003eadverse drug event\u003c/b\u003e,\" \"\u003cb\u003epatient safety\u003c/b\u003e\"), phases of the medication process (including \"\u003cb\u003eprescribing\u003c/b\u003e,\" \"\u003cb\u003edispensing\u003c/b\u003e,\" \"\u003cb\u003eadministration\u003c/b\u003e\"), and outcomes of interventions (like \"\u003cb\u003eprevention\u003c/b\u003e,\" \"\u003cb\u003ereduction\u003c/b\u003e,\" and \"\u003cb\u003eidentification\u003c/b\u003e\").\u003c/p\u003e\u003cp\u003eTo maintain both currency and relevance, the search was confined to articles published between January 2010 and May 2025. Only those articles published in English were deemed suitable for inclusion. Reference management tools, such as Zotero or Mendeley, were employed to arrange the search results, eliminate duplicates, and assist in managing citations.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\u003ch2\u003e2.2 Inclusion and Exclusion Criteria\u003c/h2\u003e\u003cp\u003eThe articles identified during the literature search were subjected to a comprehensive two-step screening process, following predefined inclusion and exclusion criteria.\u003c/p\u003e\u003cdiv id=\"Sec13\" class=\"Section3\"\u003e\u003ch2\u003e2.2.1 Inclusion Criteria\u003c/h2\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003eOriginal Research studies (for instance, randomised controlled trials, observational studies, and quasi-experimental studies) that specifically examine the involvement of pharmacists in the prevention, identification, or reduction of medication errors.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eComprehensive reviews and meta-analyses concerning pharmacist interventions that pertain to medication safety.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eInvestigations that concentrate on any phase of the medication utilisation process, including prescribing, transcribing or order entry, dispensing, or administration.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003ePublications that appear in peer-reviewed academic journals.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eResearch involving human participants.\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec14\" class=\"Section3\"\u003e\u003ch2\u003e2.2.2 Exclusion Criteria\u003c/h2\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003eEditorials, opinion pieces, letters to the editor, commentaries, conference abstracts, or book chapters (except for systematic reviews).\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eResearch which is primarily centred on medication errors that do not involve pharmacist interventions.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eArticles that are not accessible in full text or are not published in the English language.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eStudies concerning interventions exclusively conducted by healthcare professionals who are not pharmacists.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eResearch involving animals or laboratory-based investigations.\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e\u003ch2\u003e2.3 Screening Process\u003c/h2\u003e\u003cp\u003eThe study selection process was conducted independently by two authors (the first and second authors) to minimise selection bias. Initially, titles and abstracts of identified articles were screened based on predefined inclusion and exclusion criteria. Subsequently, full texts of potentially relevant studies were assessed for eligibility. Disagreements between the two reviewers\u0026mdash;such as differing interpretations of eligibility criteria, unclear study relevance, or varying judgments on study quality\u0026mdash;were resolved through discussion and mutual consensus. When consensus could not be reached, the third author was consulted to provide a final decision. This systematic approach ensures transparency and rigour in study selection\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e and is visually summarised in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e (PRISMA flow diagram)\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\u003ch2\u003e2.4 Data Extraction\u003c/h2\u003e\u003cp\u003eFor each article included in the review, pertinent data were gathered utilising a standardised and pre-tested data extraction form. The data points that were extracted encompassed:\u003c/p\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003eAuthor(s) and the year of publication.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eStudy design (for instance, RCT, cohort, cross-sectional).\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eStudy setting (such as hospital, community pharmacy, primary care).\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eCharacteristics of the population (including patient demographics and sample size).\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eThe specific type of medication error that was addressed (for example, prescribing errors or dispensing errors).\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eDetails regarding the pharmacist intervention (including medication reconciliation, patient counselling, and clinical review).\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eOutcomes that were measured (such as error rate reduction, adverse drug event reduction, and cost savings).\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eSignificant findings and conclusions about the role of the pharmacist.\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003cp\u003eThe data extraction process was conducted by the first author and was independently verified by a second author to guarantee both accuracy and completeness.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e\u003ch2\u003e2.5 Data Synthesis\u003c/h2\u003e\u003cp\u003eA narrative synthesis methodology\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e was utilised to analyse and present the collected data. The findings were thematically organised, primarily structured around the stages of the medication use process: prescription, transcribing/order entry, dispensing, and administration. Within each stage, pharmacist interventions, their effectiveness, and associated outcomes were thoroughly examined. Furthermore, overarching themes such as interprofessional collaboration, the impact of technology, and pharmacist-facilitated patient education were included. The synthesis also evaluated the effectiveness of these interventions within Indian and comparable low- and middle-income country (LMIC) contexts, along with challenges to their implementation and the underreporting of medication errors. Lastly, the strengths and weaknesses of the evidence base were assessed, and gaps in current research were identified to inform future investigations.\u003c/p\u003e\u003c/div\u003e"},{"header":"3. RESULTS","content":"\u003cp\u003eA total of 29 studies that met the eligibility criteria, published from 2010 to 2024, were incorporated into this review. The majority, exceeding 65%, were prospective observational studies carried out in tertiary care hospitals located in India, covering states such as Karnataka, Tamil Nadu, Telangana, West Bengal, and Uttarakhand. The primary emphasis of most studies was on the phases of prescribing and administering medications.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.1 Prevalence of Medication Errors\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe reported prevalence of medication errors exhibited considerable variation across different studies. For example, Bhowmick et al. in 2020 reported an exceptionally low rate of 0.0017% (88 errors out of 50,822 patients) in a three-year passive surveillance study conducted in Eastern India, indicating potential underreporting in passive monitoring systems\u003cstrong\u003e\u003csup\u003e12\u003c/sup\u003e\u003c/strong\u003e. Conversely, Chaithra et al. in 2023 recorded a ME rate of 26.81% in a tertiary hospital in South India, which showed a reduction from 36.11% following multiple sensitisation programs directed at healthcare professionals\u003cstrong\u003e\u003csup\u003e5\u003c/sup\u003e\u003c/strong\u003e. Kapil et al. (2020) reported a 6.11% occurrence of medication errors (MEs) in critical care settings, which included transcription errors at 44.1%, prescription errors at 40%, and administration errors at 14%\u003cstrong\u003e\u003csup\u003e17\u003c/sup\u003e\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.2 Types and Stages of Errors\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePrescribing errors were prevalent in nearly all studies, representing as much as 92.2% of total errors in certain reports\u003cstrong\u003e\u003csup\u003e5\u003c/sup\u003e\u003c/strong\u003e. Administration errors were also frequently observed, with Bhowmick et al. in 2020\u003cstrong\u003e\u003csup\u003e12\u003c/sup\u003e\u003c/strong\u003e noting their occurrence in 69.3% of the identified errors. In contrast, errors related to dispensing, documentation, and monitoring were significantly less common, generally falling within the range of 3\u0026ndash;5%\u003cstrong\u003e\u003csup\u003e12\u003c/sup\u003e\u003c/strong\u003e. Kapil et al. in 2020 \u003cstrong\u003e\u003csup\u003e17\u003c/sup\u003e\u003c/strong\u003e reported a 6.11% occurrence of medication errors (MEs) in critical care settings, which included transcription errors at 44.1%, prescription errors at 40%, and administration errors at 14%. In 2023, Aradhya et al. reported that there were 41.5% prescribing errors, 33.8% documentation errors, and 21.1% administration errors occurring in Intensive Care Units (ICUs)\u003cstrong\u003e\u003csup\u003e10\u003c/sup\u003e\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFrequently noted prescription-related errors encompassed:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e- Exclusion of generic medication names (73%)\u003c/p\u003e\n\u003cp\u003e- Missing dosage details (48.5%)\u003c/p\u003e\n\u003cp\u003e- Failure to specify routes of administration (35.2%)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.3 Drug Classes and Severity\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAntibiotics, Non-steroidal Anti-Inflammatory drugs (NSAIDs), and cardiovascular medications were the most commonly linked to MEs. Ceftriaxone, Diclofenac, and Insulin emerged as the drugs most susceptible to errors, frequently referenced across various studies\u003cstrong\u003e\u003csup\u003e2, 18\u003c/sup\u003e\u003c/strong\u003e. Additionally, high-alert medications (HAMs) such as Potassium Chloride, Tramadol, and Propranolol were consistently identified as problematic.\u003c/p\u003e\n\u003cp\u003eThe categorisation by NCC MERP was utilised in more than 70% of the studies: \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e- Errors classified as Category B (those that occurred but did not reach the patient) made up the majority (~94.8%) in numerous contexts. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e- A limited number of studies documented Category D\u0026ndash;F errors (which did reach the patient and necessitated monitoring or intervention).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.4 Pharmacist Interventions and Impact\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eClinical pharmacist-led interventions were evaluated in more than one-third of the studies included in the analysis. These interventions encompassed:\u003c/p\u003e\n\u003cp\u003e- Auditing prescriptions and verifying dosages\u003c/p\u003e\n\u003cp\u003e- Organising sensitisation workshops for nursing staff and junior physicians\u003c/p\u003e\n\u003cp\u003e- Supplying medication safety charts, feedback forms, and reporting instruments\u003c/p\u003e\n\u003cp\u003eSignificantly, Mohan et al. conducted a sensitisation initiative in ICU environments in 2019\u003cstrong\u003e\u003csup\u003e8\u003c/sup\u003e\u003c/strong\u003e, which resulted in a marked decrease in prescription mistakes; however, the overall reporting continued to be low due to cultural barriers. In 2024, Shanmugapriya et al. highlighted the insufficient use of pharmacists in Indian healthcare facilities, advocating for the incorporation of clinical pharmacists into routine rounds and prescribing processes \u003cstrong\u003e\u003csup\u003e2\u003c/sup\u003e\u003c/strong\u003e. A prospective investigation conducted in 2022 by Mandeep Kumar et al. identified 271 medication errors (122.6 per 1,000 patient-days) within the intensive care unit; 86% of the recommendations made by pharmacists were accepted, which notably decreased the occurrence of preventable adverse drug events\u003cstrong\u003e\u003csup\u003e19\u003c/sup\u003e\u003c/strong\u003e.\u003c/p\u003e"},{"header":"4. DISCUSSION","content":"\u003cp\u003eThe findings compiled in this review highlight the complex and essential function of pharmacists in improving medication safety. At every phase of the medication use process\u0026mdash;from prescribing through to administration and monitoring\u0026mdash;pharmacists carry out specific interventions that not only minimise errors but also enhance clinical outcomes. In this analysis, we explore these contributions thoroughly, place their effectiveness within different healthcare environments, and emphasise the elements that influence their impact.\u003c/p\u003e\u003cdiv id=\"Sec24\" class=\"Section2\"\u003e\u003ch2\u003e4.1 Prescribing Stage\u003c/h2\u003e\u003cp\u003e\u003cb\u003eIdentification and Correction of Prescribing Errors\u003c/b\u003e\u003c/p\u003e\u003cp\u003eKandasamy et al. conducted a cross-sectional study in 2021 involving 500 outpatient prescriptions at a corporate hospital in South India\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. They found that at least one prescribing error occurred in 32.6% of the cases, alongside a dispensing error rate of 37.8%. The errors predominantly included incorrect dosages, omissions, and illegible handwriting, underscoring the critical need for pharmacist-led interventions during the prescription entry process. Pharmacists have played a crucial role in minimising medication omissions, such as absent dosage or frequency, and preventing drug-drug interactions. This has been achieved through a thorough clinical review of prescriptions to ensure dose accuracy and clarity, effective communication with prescribers, and comprehensive patient education.\u003c/p\u003e\u003cp\u003eMoreover, an observational study carried out in Karnataka\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e indicated that a considerable number of prescriptions were missing vital elements, including patient demographic information, prescriber identification, and accurate dosage instructions. The absence of these components not only undermined the clarity and legality of the prescriptions but also created significant difficulties for pharmacists during the verification and dispensing stages. Incomplete prescriptions heighten the risk of errors such as providing the incorrect medication, administering the wrong dosage, or giving medication to the wrong patient, especially in high-volume outpatient environments where pharmacists are required to handle numerous prescriptions within constrained timeframes. These findings highlight the urgent necessity for pharmacist participation in the screening and validation of prescriptions, alongside the adoption of standardised prescription formats and training initiatives aimed at minimising ambiguity and enhancing interprofessional communication.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec25\" class=\"Section2\"\u003e\u003ch2\u003e4.2 Dispensing and Transcribing Stage\u003c/h2\u003e\u003cp\u003e\u003cb\u003eError surveillance and reporting initiatives\u003c/b\u003e\u003c/p\u003e\u003cp\u003eIn 2018, Chalasani et al. established a non-punitive reporting system within an Indian teaching hospital, identifying 1,310 medication errors, which corresponds to a 6.4% incidence rate, across the processes of prescribing, transcribing, and administration over a span of three years\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. Interventions included a pharmacist-led root cause analysis, provision of feedback to the staff, and recommendations for redesigning workflows. The outcomes demonstrated an enhanced culture of reporting, especially among nurses and junior doctors, along with increased transparency in the tracking of errors.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec26\" class=\"Section2\"\u003e\u003ch2\u003e4.3 Administration \u0026amp; Monitoring Stage\u003c/h2\u003e\u003cp\u003e\u003cb\u003eICU-based Pharmacist Interventions\u003c/b\u003e\u003c/p\u003e\u003cp\u003eNeelima Ganzi et al. in 2024 conducted a study on critically ill patients admitted in Intensive Care Units of a South Indian Tertiary Care Teaching Hospital, where pharmacists were responsible for performing medication reconciliation and reviewing dose adjustments\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. The inclusion of clinical pharmacists within the MICU team has led to a decrease in the occurrence of medication-related problems (MRP), a reduction in both the duration of stay in the MICU and the overall hospital stay, and an enhancement in the health-related quality of life for patients.\u003c/p\u003e\u003cp\u003eA prospective study conducted by Aghili and Kasturirangan in the ICU from 2017 to 2019 documented a total of 271 medication errors, which translates to 122.6 errors per 1,000 patient-days\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. Among these errors, 25.8% were identified as drug\u0026ndash;drug interactions, while 18.8% were due to non-conformance with established guidelines. The acceptance rate of pharmacist recommendations was notably high at 86%, which led to a significant reduction in preventable adverse drug events (ADEs), the duration of ICU stays, the number of transfers to higher levels of care, and mortality rates within the intervention group. The interventions undertaken by pharmacists, including modifying dosages of drugs cleared by the kidneys and emphasising the risks associated with nephrotoxicity, resulted in a decrease in detrimental drug-drug interactions and dosing mistakes, even though the precise rates of this decrease were not disclosed.\u003c/p\u003e\u003cp\u003eIn a tertiary care facility located in Gujarat, research indicated that 45.9% of hospitalised patients encountered omissions and errors in documentation throughout their stay\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. These results emphasise the urgent necessity for pharmacist-led medication reconciliation services, especially during critical transitions of care, including admission, transfer, and discharge. Furthermore, the significant occurrence of these errors accentuates the need for educational initiatives directed at both patients and staff, led by clinical pharmacists, to raise awareness, refine documentation practices, and ultimately mitigate preventable harm related to medications.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec27\" class=\"Section2\"\u003e\u003ch2\u003e4.4 Types of Medication Errors addressed\u003c/h2\u003e\u003cp\u003e\u003cstrong\u003eHigh-Alert Medication Focus\u003c/strong\u003e\u003cp\u003eResearch conducted in Intensive Care Units\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e revealed that pharmacists were able to catch insulin dosing mistakes, drug incompatibilities, duplications, and renal dosing concerns\u0026mdash;frequently before patient exposure.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eDrug\u0026ndash;Drug Interactions \u0026amp; Omissions\u003c/strong\u003e\u003cp\u003eA review of prescriptions in outpatient environments successfully averted potentially dangerous combinations and minimised omission errors by recognising previously unknown interactions.\u003c/p\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec28\" class=\"Section2\"\u003e\u003ch2\u003e4.5 Interprofessional Collaboration\u003c/h2\u003e\u003cp\u003ePharmacist-led interventions achieve maximum effectiveness when integrated into a multidisciplinary care framework. The collaboration between pharmacists and other healthcare professionals, especially physicians and nurses, is essential not only for the successful execution of interventions but also for enhancing the overall safety culture within the institution. In various studies conducted in ICUs and MICUs across India\u003csup\u003e\u003cb\u003e\u003cspan additionalcitationids=\"CR23\" citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e, pharmacists played a crucial role as active members of the clinical care team, engaging in ward rounds, patient case discussions, and real-time therapeutic decision-making.\u003c/p\u003e\u003cp\u003eFor instance, during the prospective ICU study conducted from 2017 to 2019\u003csup\u003e\u003cb\u003e23\u003c/b\u003e\u003c/sup\u003e, structured clinical meetings between pharmacists and intensivists facilitated the swift identification and correction of drug-related problems (DRPs). These meetings involved real-time chart evaluations, the identification of high-risk medications (including insulin, anticoagulants, and nephrotoxic agents), and dose modifications based on renal or hepatic function. Notably, these interactions established a continuous feedback mechanism, where pharmacists\u0026rsquo; recommendations were accepted by physicians in over 85% of instances and were valued for their contribution to preventing preventable adverse drug events (pADEs) and optimising therapy.\u003c/p\u003e\u003cp\u003eChalasani et al. in 2018\u003csup\u003e\u003cb\u003e22\u003c/b\u003e\u003c/sup\u003e further illustrated how interprofessional collaboration can be institutionalised through systems-based strategies. Their pharmacist-initiated medication error reporting program included a collaborative analysis of reported incidents, incorporating insights from pharmacists, physicians, nurses, and administrative personnel. This method not only enabled precise classification and root-cause analysis of errors but also resulted in significant modifications to hospital protocols, such as the standardisation of prescription formats and the implementation of error-prevention alerts in manual prescription systems. The initiative contributed to the development of a non-punitive, learning-oriented culture, encouraging healthcare professionals at all levels to report and discuss errors without the fear of retribution.\u003c/p\u003e\u003cp\u003eFurthermore, in environments where resources are constrained, such as public sector hospitals, pharmacists frequently assume a mediating role between clinical and administrative departments. Their participation in discussions at the policy level about formulary choices, medication usage protocols, or evaluations of drug utilisation enhances the effectiveness of patient safety initiatives. A recent study conducted in India by Neelima Ganzi et al. \u003csup\u003e\u003cb\u003e23\u003c/b\u003e\u003c/sup\u003e has underscored that when pharmacists collaborate effectively with physicians and nursing staff, there is a significant enhancement not only in the safety of medications but also in the satisfaction of staff, compliance with treatment protocols, and the clarity of communication during shift changes.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec29\" class=\"Section2\"\u003e\u003ch2\u003e4.6 Technological Integrations in Indian Medication Safety Initiatives\u003c/h2\u003e\u003cp\u003eEven though Indian studies have not yet conducted direct evaluations of systems such as Computerised Physician Order Entry (CPOE), Barcode Medication Administration (BCMA), or Electronic Health Records (EHRs), recent initiatives aimed at quality improvement reveal promising initial results. In a prominent tertiary care hospital located in Kolkata, a Point-of-Care Quality Improvement initiative, which is following WHO‑POCQI, executed software-generated prescriptions through four Plan\u0026ndash;Do\u0026ndash;Study\u0026ndash;Act (PDSA) cycles\u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. This intervention led to a reduction in medication errors from a baseline of 63% to merely 10.4% over a span of nine months, thereby significantly enhancing the accuracy of doses, timing, infusion rates, and the quality of documentation.\u003c/p\u003e\u003cp\u003eAlthough traditional BCMA systems have not yet achieved widespread implementation in India, the Kolkata QI project\u0026rsquo;s utilisation of computer-generated prescriptions, coupled with integrated digital checks, signifies a significant advancement towards electronic medication safety. By enhancing standardisation, improving legibility, and incorporating vital order information, this model establishes a solid groundwork for the future integration of barcoding and comprehensive EHR systems.\u003c/p\u003e\u003cp\u003eThese Indian experiences, albeit limited, offer persuasive evidence: even minor digital interventions, when paired with a structured pharmacist review, can substantially decrease medication errors and improve overall safety. They bolster broader policy recommendations aimed at expanding these technologies throughout public and private hospitals, especially when aligned with enhanced clinical pharmacy services.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec30\" class=\"Section2\"\u003e\u003ch2\u003e4.7 Challenges and Barriers\u003c/h2\u003e\u003cp\u003e\u003cstrong\u003eUnder-reporting \u0026amp; Cultural Issues\u003c/strong\u003e\u003cp\u003ePassive systems miss many errors; voluntary reporting by pharmacists encourages openness, but cultural barriers remain.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eWorkload and Resources\u003c/strong\u003e\u003cp\u003eHeavy patient loads and limited pharmacist staffing reduce the capacity for real-time prescription and administration review in multifaceted Indian settings.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eAuthority and Collaboration\u003c/strong\u003e\u003cp\u003eAcceptance rates vary; ICU interventions saw high acceptance, while outpatient settings face resistance due to hierarchy or added workflow.\u003c/p\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec31\" class=\"Section2\"\u003e\u003ch2\u003e4.8 Policy and Practice Recommendations\u003c/h2\u003e\u003cp\u003e\u003cstrong\u003eIncorporate Pharmacists into Clinical Teams\u003c/strong\u003e\u003cp\u003ePosition clinical pharmacists within wards, intensive care units, and outpatient clinics to improve the review of prescriptions and provide patient counselling.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eEstablish Structured Reporting\u003c/strong\u003e\u003cp\u003eA nationwide implementation of pharmacist-led error reporting initiatives, accompanied by anonymised multidisciplinary review forums.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eAdopt Technology\u003c/strong\u003e\u003cp\u003eHealthcare facilities ought to implement Computerised Physician Order Entry (CPOE), barcoding, and integrated monitoring systems concurrently with the activities of clinical pharmacists.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eEducation and Awareness\u003c/strong\u003e\u003cp\u003eConduct regular interprofessional training sessions aimed at promoting a non-punitive safety culture and enhancing awareness of best practices in medication safety.\u003c/p\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec32\" class=\"Section2\"\u003e\u003ch2\u003e4.9 Towards a Pharmacist-Driven Medication Safety Culture\u003c/h2\u003e\u003cp\u003eIn summary, the results of this extensive review underscore the essential function of pharmacists in ensuring the safe use of medications throughout the healthcare spectrum. Interventions led by pharmacists\u0026mdash;including prescription audits, dose modifications, reconciliation efforts, participation in interdisciplinary rounds, and the establishment of error reporting systems\u0026mdash;have consistently proven their effectiveness in reducing medication errors, particularly in high-risk and resource-limited settings. Although there are ongoing institutional and technological obstacles, especially within numerous Indian healthcare environments, innovative models illustrate how focused pharmacist participation can markedly enhance patient safety outcomes. As India progresses in expanding its clinical pharmacy workforce and investigates digital advancements in healthcare delivery, the incorporation of pharmacists into patient care teams emerges as a practical, evidence-supported approach to mitigating preventable harm. The findings from this review lay a robust groundwork for the enhancement of national policies, institutional practices, and future research directed at optimising medication safety through pharmacist involvement.\u003c/p\u003e\u003c/div\u003e"},{"header":"5. CONCLUSION","content":"\u003cp\u003eThis review underscores the essential and complex role that pharmacists play in minimising medication errors throughout every phase of the medication use process\u0026mdash;from prescription and transcribing to dispensing, administration, and monitoring. The evidence compiled from both Indian and selected international studies indicates that interventions led by pharmacists not only diminish the frequency of errors but also improve therapeutic outcomes, reduce adverse drug events, and facilitate cost-effective healthcare delivery. Clinical pharmacists are in a unique position to conduct medication reconciliation, detect drug\u0026ndash;drug interactions, optimise dosages, educate patients, and engage in multidisciplinary care teams.\u003c/p\u003e\u003cp\u003eIn the context of Indian healthcare, despite facing infrastructural and systemic challenges, emerging research illustrates the increasing potential for pharmacist involvement in enhancing medication safety. These interventions are particularly effective in high-risk settings such as intensive care units (ICUs) and in situations where polypharmacy, inadequate documentation, or insufficient staffing elevate the likelihood of errors. Furthermore, the incorporation of pharmacists into standard clinical practices, bolstered by technological advancements like computerised physician order entry (CPOE) and electronic reporting systems, can further fortify safety protocols.\u003c/p\u003e\u003cp\u003eTo propel this advancement, there is an urgent requirement for policy-level integration of pharmacists into healthcare delivery systems, the establishment of structured reporting mechanisms, the expansion of clinical pharmacy services, and the promotion of interdisciplinary collaboration. Future research should prioritise large-scale, multi-centre studies and real-time assessments of pharmacist interventions to produce comprehensive national data. Ultimately, investing in the role of pharmacists transcends mere operational improvement\u0026mdash;it represents a strategic necessity to ensure safer, more accountable, and patient-centred healthcare in India.\u003c/p\u003e"},{"header":"6. LIMITATIONS","content":"\u003cp\u003eThis review provides a thorough examination of the pharmacist's role in mitigating medication errors; however, it is important to recognise certain limitations. First, the majority of the studies included were observational, which restricts the capacity to establish causal relationships. Second, there is a notable lack of large-scale, multi-centre research from India, as most of the data is derived from individual institutions, potentially impacting the generalizability of the findings. Third, there may be publication bias present due to the omission of articles published in non-English languages and grey literature. Finally, despite careful screening processes, some pertinent studies may have been unintentionally overlooked because of limitations in database indexing or inconsistent use of keywords.\u003c/p\u003e"},{"header":"7. FUTURE DIRECTIONS","content":"\u003cp\u003eFuture research should focus on conducting extensive, multi-centre studies across a variety of healthcare environments in India to yield data that is both generalisable and relevant to policy-making. Furthermore, there is an urgent requirement for interventional research that assesses the effects of specific initiatives led by pharmacists, employing standardised outcome measures. The evaluation of digital tools, including electronic prescribing systems, barcoding, and real-time clinical decision support, should occur alongside the involvement of pharmacists. Moreover, it is crucial to create national-level frameworks that require the integration of clinical pharmacists into healthcare teams and the establishment of systematic medication safety reporting mechanisms. Policy measures that encourage interprofessional collaboration and formalise the role of pharmacists in ensuring medication safety are vital for achieving lasting improvements.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003e\u003cstrong\u003eADR \u0026ndash;\u0026nbsp;\u003c/strong\u003eAdverse Drug Reaction\u003cbr\u003e\u003cstrong\u003eADE \u0026ndash;\u0026nbsp;\u003c/strong\u003eAdverse Drug Event\u003cbr\u003e\u003cstrong\u003eBCMA \u0026ndash;\u0026nbsp;\u003c/strong\u003eBarcode Medication Administration\u003cstrong\u003e\u003cbr\u003eCINAHL \u0026ndash;\u0026nbsp;\u003c/strong\u003eCumulative Index to Nursing and Allied Health Literature\u003cstrong\u003e\u003cbr\u003eCPOE \u0026ndash;\u0026nbsp;\u003c/strong\u003eComputerised Physician Order Entry\u003cbr\u003e\u003cstrong\u003eDRP \u0026ndash;\u0026nbsp;\u003c/strong\u003eDrug-Related Problem\u003cstrong\u003e\u003cbr\u003eEHR \u0026ndash;\u0026nbsp;\u003c/strong\u003eElectronic Health Record\u003cbr\u003e\u003cstrong\u003eHAM \u0026ndash;\u0026nbsp;\u003c/strong\u003eHigh-Alert Medication\u003cstrong\u003e\u003cbr\u003eICU \u0026ndash;\u0026nbsp;\u003c/strong\u003eIntensive Care Unit\u003cstrong\u003e\u003cbr\u003eLMIC \u0026ndash;\u0026nbsp;\u003c/strong\u003eLow- and Middle-Income Countries\u003cstrong\u003e\u003cbr\u003eME \u0026ndash;\u0026nbsp;\u003c/strong\u003eMedication Error\u003cstrong\u003e\u003cbr\u003eMICU \u0026ndash;\u0026nbsp;\u003c/strong\u003eMedical Intensive Care Unit\u003cstrong\u003e\u003cbr\u003eNCC MERP \u0026ndash;\u0026nbsp;\u003c/strong\u003eNational Coordinating Council for Medication Error Reporting and Prevention\u003cbr\u003e\u003cstrong\u003eNSAID \u0026ndash;\u0026nbsp;\u003c/strong\u003eNon-Steroidal Anti-Inflammatory Drug\u003cstrong\u003e\u003cbr\u003ePDSA \u0026ndash;\u0026nbsp;\u003c/strong\u003ePlan\u0026ndash;Do\u0026ndash;Study\u0026ndash;Act\u003cstrong\u003e\u003cbr\u003epADE \u0026ndash;\u0026nbsp;\u003c/strong\u003ePreventable Adverse Drug Event\u003cstrong\u003e\u003cbr\u003ePCI \u0026ndash;\u0026nbsp;\u003c/strong\u003ePharmacy Council of India\u003cstrong\u003e\u003cbr\u003ePRISMA \u0026ndash;\u0026nbsp;\u003c/strong\u003ePreferred Reporting Items for Systematic Reviews and Meta-Analyses\u003cstrong\u003e\u003cbr\u003eRCT \u0026ndash;\u0026nbsp;\u003c/strong\u003eRandomised Controlled Trial\u003cstrong\u003e\u003cbr\u003eWHO \u0026ndash;\u0026nbsp;\u003c/strong\u003eWorld Health Organisation\u003cstrong\u003e\u003cbr\u003eWHO-POCQI \u0026ndash;\u0026nbsp;\u003c/strong\u003eWorld Health Organisation \u0026ndash; Point of Care Quality Improvement\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003e8. ACKNOWLEDGEMENTS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors wish to convey their heartfelt appreciation to Prof. Rama Rao Nadendla, Principal of Chalapathi Institute of Pharmaceutical Sciences in Lam, Guntur, for his unwavering encouragement and assistance during the development of this review. The authors further recognise the invaluable contributions of the institutional library team for facilitating access to crucial academic databases and resources.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e9. FUNDING STATEMENT\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo funding was received for the preparation of this review article.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e10. CONFLICTS OF INTEREST\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no conflicts of interest related to this work.\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003ePKY conceptualized the review, supervised the overall study, and critically revised the manuscript. LG performed the literature search, data extraction, and initial drafting of the manuscript. LPY contributed to data organization, synthesis of key findings, and manuscript editing. RRN provided expert guidance, validated the interpretations, and reviewed the final draft for intellectual content. All authors read and approved the final version of the manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eMedication Error Definition [Internet]. Available from: https://www.nccmerp.org/about-medication-errors [Accessed 2025 Jun 8].\u003c/li\u003e\n\u003cli\u003eShanmugapriya J, Mehta S, Garg S, Saxena T, Sharma N, Goswami G. Unravelling medication errors in Indian scholarly articles (2010\u0026ndash;2023): A comprehensive review. Muller Journal of Medical Sciences and Research [Internet]. 2024 Jul 1;15(2):136\u0026ndash;44. Available from: https://journals.lww.com/mjmr/fulltext/2024/15020/unraveling_medication_errors_in_indian_scholarly.9.aspx\u003c/li\u003e\n\u003cli\u003eWorld Health Organisation: WHO. Patient safety [Internet]. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/patient-safety [Accessed 2025 Jun 8].\u003c/li\u003e\n\u003cli\u003eWorld Health Organisation. Medication Without Harm. Geneva: World Health Organisation; 2017. Available from: https://iris.who.int/bitstream/handle/10665/255263/WHO-HIS-SDS-2017.6-eng.pdf?sequence=1 [Accessed 2025 Jun 8].\u003c/li\u003e\n\u003cli\u003eChaithra K, Sparshadeep E, Priyadarshini B, Rajesh B, Kavana V, Shabeena B, et al. Evaluation of pattern of medication errors in a tertiary care hospital in South India: A prospective observational study. National Journal of Physiology, Pharmacy and Pharmacology [Internet]. 2023 Jan 1;13(8):1. Available from: https://www.njppp.com/index.php?mno=157433\u003c/li\u003e\n\u003cli\u003eRasool MF, Rehman AU, Imran I, Abbas S, Shah S, Abbas G, et al. Risk factors associated with medication errors among patients suffering from chronic disorders. Frontiers in Public Health [Internet]. 2020 Nov 19;8. Available from: https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2020.531038/full\u003c/li\u003e\n\u003cli\u003ePauldine B. Acute care [Internet]. ECRI and ISMP. 2024. Available from: https://home.ecri.org/blogs/ismp-resources/high-alert-medications-in-acute-care-settings\u003c/li\u003e\n\u003cli\u003eMohan A, Manikandan S, Ravikumar TS, Batmanabane G. Decreasing medication errors in four intensive care units of a tertiary care teaching hospital in India using a sensitisation programme. The National Medical Journal of India [Internet]. 2019 Jan 1;32(4):207. Available from: https://nmji.in/decreasing-medication-errors-in-four-intensive-care-units-of-a-tertiary-care-teaching-hospital-in-india-using-a-sensitization-programme/\u003c/li\u003e\n\u003cli\u003eMitra M, Basu M. An analysis of medication errors in a tertiary care teaching hospital [Internet]. Available from: https://www.jrmds.in/articles/an-analysis-of-medication-errors-in-a-tertiary-care-teaching-hospital-53272.html\u003c/li\u003e\n\u003cli\u003eAradhya PJ, Ravi R, Chandra BJS, Ramesh M, Chalasani SH. Assessment of Medication Safety Incidents Associated with High-alert Medication Use in Intensive Care Setting: A Clinical Pharmacist Approach. Indian Journal of Critical Care Medicine [Internet]. 2023 Nov 28;27(12):917\u0026ndash;22. Available from: https://www.ijccm.org/abstractArticleContentBrowse/IJCCM/64/27/12/34591/abstractArticle/Article\u003c/li\u003e\n\u003cli\u003ePharmacy Council of India. Amendment to Education Regulations, 1991 for the Diploma Course in Pharmacy [Internet]. New Delhi: Pharmacy Council of India; 2014 [cited 2025 Jun 8]. Available from: https://www.pci.nic.in/pdf/14-150%20amendment%20web.pdf\u003c/li\u003e\n\u003cli\u003eBhowmick S, Jana S, Bandyopadhyay A, Kundu D, Banerjee M, Das A, et al. Medication errors reported in a tertiary care private hospital in Eastern India: a three-year experience. International Journal of Basic \u0026amp; Clinical Pharmacology [Internet]. 2020 May 21;9(6):937. Available from: https://www.ijbcp.com/index.php/ijbcp/article/view/4124\u003c/li\u003e\n\u003cli\u003eMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ [Internet]. 2009 Jul 21;339(jul21 1): b2535. Available from: https://www.bmj.com/content/339/bmj.b2535\u003c/li\u003e\n\u003cli\u003eHaddaway, N. R., Page, M. J., Pritchard, C. C., \u0026amp; McGuinness, L. A. (2022). PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis Campbell Systematic Reviews, 18, e1230. https://doi.org/10.1002/cl2.1230\u003c/li\u003e\n\u003cli\u003ePRISMA Flow Diagram [Internet]. Available from: https://estech.shinyapps.io/prisma_flowdiagram/\u003c/li\u003e\n\u003cli\u003eArai L, Rodgers A, Roberts H, Popay J, Roen K, Wright N. Testing methodological developments in the conduct of narrative synthesis: a demonstration review of research on the implementation of smoke alarm interventions [Internet]. Lancaster: Lancaster University; 2007 [cited 2025 Jun 8]. Available from: https://www.lancaster.ac.uk/media/lancaster-university/content-assets/documents/fhm/dhr/chir/Rodgersetal.pdf\u003c/li\u003e\n\u003cli\u003eZirpe KG, Seta B, Gholap S, Aurangabadi K, Gurav SK, Deshmukh AM, et al. Incidence of Medication Error in Critical Care Unit of a Tertiary Care Hospital: Where Do We Stand? Indian J Crit Care Med 2020;24(9):799\u0026ndash;803.Available from: https://www.ijccm.org/doi/pdf/10.5005/jp-journals-10071-23556\u003c/li\u003e\n\u003cli\u003eMugada V, Devineni RC, Pendyala RM, Vempati D, Kuchi S. Categorisation, Appraisal, and Reporting of Medication Errors Ascertained in Medical Ward of Tertiary Care Hospital. J App Pharm Sci [Internet]. 2018 [cited 2025 Jun 8];8(05):109\u0026ndash;14. Available from: https://japsonline.com/admin/php/uploads/2632_pdf.pdf\u003c/li\u003e\n\u003cli\u003eKumar M, Sahni N, Shafiq N, Yaddanapudi LN. Medication prescription errors in the intensive care unit: Prospective observational study. Indian J Crit Care Med. 2022 May;26(5):555-559. Available from: https://www.ijccm.org/doi/pdf/10.5005/jp-journals-10071-24148\u003c/li\u003e\n\u003cli\u003eKandasamy G, Sivanandy P, Almaghaslah D, Almanasef M, Vasudevan R, Chinnadhurai M, et al. A cross‐sectional study on prescribing and dispensing errors at a corporate hospital in South India. International Journal of Clinical Practice [Internet]. 2021 Jun 11;75(9). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/ijcp.14489\u003c/li\u003e\n\u003cli\u003eP RA, Vishwas HN, Hosur SS, K A V, S K. A study of prescription errors in South Indian City, Karnataka- An observational study. IP International Journal of Comprehensive and Advanced Pharmacology [Internet]. 2023 May 15;8(2):125\u0026ndash;9. Available from: https://www.ijcap.in/html-article/18897\u003c/li\u003e\n\u003cli\u003eChalasani SH, Ramesh M, Gurumurthy P. Pharmacist-Initiated Medication Error-Reporting and Monitoring Programme in a developing country scenario. Pharmacy [Internet]. 2018 Dec 14;6(4):133. Available from: https://www.mdpi.com/2226-4787/6/4/133\u003c/li\u003e\n\u003cli\u003eGanzi N, Sanathan SR, Jayaram SCB, Vigneshwaran E. Clinical Pharmacist-Initiated Interventions for Medication-Related Problems in the Medical Intensive Care Unit of a teaching university hospital in South India: a prospective observational study. International Journal of Pharmaceutical Investigation [Internet]. 2024 Dec 5;15(1):131\u0026ndash;7. Available from: https://jpionline.org/article/33884\u003c/li\u003e\n\u003cli\u003eAghili M, Kasturirangan MN. A clinical pharmacist-led integrated approach for evaluation of medication errors among medical intensive care unit patients. JBI Evidence Implementation [Internet]. 2020 Jun 9;19(1):21\u0026ndash;30. Available from: https://journals.lww.com/ijebh/abstract/2021/03000/a_clinical_pharmacist_led_integrated_approach_for.5.aspx\u003c/li\u003e\n\u003cli\u003ePatel S, Patel A, Patel V, Solanki N. Study of medication error in hospitalised patients in a Tertiary Care hospital. Indian Journal of Pharmacy Practice [Internet]. 2018 Mar 6;11(1):32\u0026ndash;6. Available from: https://www.researchgate.net/publication/323589950_Study_of_Medication_Error_in_Hospitalised_Patients_in_Tertiary_Care_Hospital\u003c/li\u003e\n\u003cli\u003ePote S, Tiwari P, D\u0026rsquo;Cruz S. Medication prescribing errors in a public teaching hospital in India: a prospective study [Internet]. Available from: https://scielo.isciii.es/scielo.php?script=sci_abstract\u0026amp;pid=S1885642X2007000100003\u0026amp;lng=es\u0026amp;nrm=iso\u0026amp;tlng=en\u003c/li\u003e\n\u003cli\u003eHisham M, Sivakumar MN, Veerasekar G. Impact of clinical pharmacist in an Indian intensive care unit. \u003cem\u003eIndian J Crit Care Med\u003c/em\u003e. 2016;20(2):78\u0026ndash;83. Available from: https://www.ijccm.org/doi/pdf/10.4103/0972-5229.175931\u003c/li\u003e\n\u003cli\u003eMondal S, Banerjee M, Mandal S, Mallick A, Das N, Basu B, et al. An initiative to reduce medication errors in the neonatal care unit of a tertiary care hospital, Kolkata, West Bengal: a quality improvement report. BMJ Open Quality [Internet]. 2022 May 11;11(Suppl 1): e001468. Available from: https://bmjopenquality.bmj.com/content/11/Suppl_1/e001468\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Pharmacist Interventions, Medication Errors, Patient Safety, Clinical Pharmacy, Medication Reconciliation, Prescribing Safety","lastPublishedDoi":"10.21203/rs.3.rs-7829270/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7829270/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground: \u003c/strong\u003eMedication errors constitute a significant global public health issue, leading to preventable morbidity, mortality, and increased healthcare expenditures. In India, the risks are heightened by disjointed prescribing practices, polypharmacy, and insufficient staffing within healthcare systems. Pharmacists are increasingly acknowledged as vital contributors to the prevention of medication errors throughout the entire medication-use continuum.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eObjective: \u003c/strong\u003eThis comprehensive review seeks to consolidate existing evidence regarding the diverse roles and interventions of pharmacists in mitigating medication errors from the point of prescription to administration, and to pinpoint challenges and prospective avenues for future research.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods: \u003c/strong\u003eA systematic search was performed across PubMed, Scopus, Embase, Web of Science, and CINAHL for studies published between January 2010 and May 2025. The search terms encompassed “pharmacist,” “medication errors,” “medication safety,” and related terminology. Studies eligible for inclusion comprised observational studies, clinical trials, and systematic reviews that involved human participants and pharmacist-led interventions. The data were thematically analysed through narrative synthesis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003ePharmacists effectively engage at every stage: reviewing prescriptions, reconciling medications, verifying dispensing accuracy, educating patients, and monitoring adverse events. Evidence underscores their effectiveness in decreasing error rates, enhancing patient outcomes, and improving system safety. Significant barriers include inadequate staffing, communication deficiencies, and underutilization in the Indian context.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion: \u003c/strong\u003ePharmacists are crucial to ensuring medication safety. The integration of their roles within healthcare systems, along with supportive policies and targeted research, is vital to maximising their contributions.\u003c/p\u003e","manuscriptTitle":"From Prescription to Administration: A Comprehensive Review of the Pharmacist’s Role in Preventing Medication Errors","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-13 05:52:06","doi":"10.21203/rs.3.rs-7829270/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"702e26c9-1682-4bf7-92de-5ac08ccf21b2","owner":[],"postedDate":"October 13th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-11-05T10:53:43+00:00","versionOfRecord":[],"versionCreatedAt":"2025-10-13 05:52:06","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7829270","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7829270","identity":"rs-7829270","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}